Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection

Registry ID

EUCTR2014-005041-41

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Janssen Sciences Ireland UC

Start date

2015-03-20

Completion date

2015-10-02

Last update

2026-08-16

Conditions

• Respiratory Syncytial Virus

Summary

To evaluate the antiviral effect of repeated oral dosing of JNJ-53718678 compared to placebo in healthy adult subjects infected through inoculation with RSV-A Memphis 37b virus.

Locations

• , , UK

Related clinical trials

• A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
• Assessing Antiviral Treatments in Early Symptomatic RSV
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

View on source registry